Results 41 to 50 of about 102,210 (307)
EFFECTS OF DIFFERENT WARFARIN DOSES ON IL-6 AND COX-2 LEVELS
Background: Warfarin has been widely used for a long time as an oral anticoagulant agent. Warfarin is reported to have inflammatory role as well. The dose of Warfarin plays an important role in up and down regulation of interacting cytokines such as IL ...
Huma Shafiq, Amir Rashid, Asifa Majeed
doaj +2 more sources
BackgroundDespite the proven efficacy of warfarin, its use in patients with Atrial Fibrillation (AF) is reportedly low. We investigated the underuse and overuse of warfarin in the management of AF in general practices in the United Kingdom (UK) against ...
Mohammed A Mohammed +4 more
doaj +1 more source
Spontaneous abdominal hemorrhage due to warfarin treatment
Warfarin is an anticoagulant used in the prevention of thromboembolism. Common clinical indications for warfarin use are atrial fibrillation, artificial heart valves, deep venous thrombosis. Common side effect of warfarin is hemorrhage.
Mustafa Volkan Demir +3 more
doaj +1 more source
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang +12 more
wiley +1 more source
Current strategies of anticoagulation therapy for patients with non-valvular atrial fibrillation
Cardioembolic stroke accounts for 20–30% of acute brain infarctions in Japan. This condition is often severe and has poor outcomes. Non-valvular atrial fibrillation (NVAF) is the most common cardiac source of emboli in cardioembolic stroke ...
Masahiro Yasaka
doaj +1 more source
Applying machine learning to pharmacovigilance data: A proof‐of‐concept study
Aim Machine learning (ML) applications in pharmacovigilance remain limited and underexplored. Using data from the French National pharmacovigilance database (FNPV), this proof‐of‐concept study aimed to assess the feasibility of using a ML algorithm—eXtreme Gradient Boosting (XGBoost)—combined with SHapley Additive exPlanations (SHAP) analysis, to ...
Romain Barus +6 more
wiley +1 more source
Aims Pulmonary arterial hypertension (PAH) is a syndrome characterized by elevated pulmonary artery pressure. We developed a population pharmacokinetic (PPK) model using combined plasma drug concentration data from Japanese paediatric (<15 years) and adult (≥15 years) patients with PAH to investigate the pharmacokinetic characteristics of PAH ...
Motoyasu Miura +13 more
wiley +1 more source
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies +2 more
wiley +1 more source
Background The polymorphisms of VKORC1 and CYP2C9 play increasingly important roles in the inter-individual variability in warfarin dose. This study aimed to evaluate the feasibility of clinical application of pharmacogenetic-based warfarin-dosing ...
MingSong Wang, XiLong Lang, ShiTao Cui, Ke Fei, LiangJian Zou, Jia Cao, LiangXu Wang, ShengHui Zhang, XinTian Wu, YiLing Wang, Qiang Ji
doaj
Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control
Objectives: Warfarin remains widely used with a time in therapeutic range (TiTR) above 65% recommended for best outcomes. Patients not achieving or maintaining this warfarin control may be better suited to alternate anticoagulants. Despite this, there is
Bernaitis, N +4 more
core +1 more source

